Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

THOMAS L ASHCOM

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1689637027
CMS profile
302825
Location
WICHITA, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,362.89

67 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,554.71 60
Travel and Lodging $775.76 2
Education $32.42 5

By paying entity

PY2019 · entire year · sorted by reported total

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

THOMAS L ASHCOM

NPI 1689637027 · CMS profile ID 302825

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

WICHITA, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1689637027?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
THOMAS L ASHCOM, NPI 1689637027, CMS profile ID 302825. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1689637027?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). THOMAS L ASHCOM, NPI 1689637027, CMS profile ID 302825. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1689637027?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
THOMAS L ASHCOM, NPI 1689637027, CMS profile ID 302825, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–67 of 67 matching records. This page contains 17 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1689637027?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

67 matching records · $2,362.89 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 67 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–67 of 67.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $16.4903/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685591089 CMS
Siemens Medical Solutions USA, Inc. $12.1803/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 631926133 CMS
Siemens Medical Solutions USA, Inc. $1.0703/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 631926137 CMS
Siemens Medical Solutions USA, Inc. $61.8903/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 631926141 CMS
Siemens Medical Solutions USA, Inc. $713.8703/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 631926143 CMS
Gilead Sciences, Inc. $16.1803/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681474165 CMS
PFIZER INC. $11.3402/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672143153 CMS
Medtronic Vascular, Inc. $10.8802/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676854917 CMS
Novartis Pharmaceuticals Corporation $14.4402/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659179391 CMS
Medtronic Vascular, Inc. $15.1902/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 676850001 CMS
Gilead Sciences, Inc. $17.9302/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681474163 CMS
AstraZeneca Pharmaceuticals LP $16.3802/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686003091 CMS
Amarin Pharma Inc. $5.9002/01/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699070675 CMS
Amarin Pharma Inc. $97.5801/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699073711 CMS
Amgen Inc. $12.9401/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663315525 CMS
Amarin Pharma Inc. $8.7701/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699051111 CMS
Amarin Pharma Inc. $5.9001/16/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699054697 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,362.89 67
PY2020 $574.50 35
PY2021 $1,302.33 65
PY2022 $1,606.33 56
PY2023 $942.09 60
PY2024 $1,178.68 25
PY2025 $832.20 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $43,694.59 9
PY2024 Principal investigator $34,209.46 3
PY2023 Principal investigator $11,260.00 2
PY2022 Principal investigator $16,476.00 3
PY2021 Principal investigator $11,195.00 6
PY2020 Principal investigator $26,199.67 6
PY2019 Principal investigator $41,402.53 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

9 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 12/02/2025 Non-covered Recipient Entity
Kansas Heart Hospital
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220997820
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 12/02/2025 Non-covered Recipient Entity
Kansas Heart Hospital
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220997822
Principal investigator 1 Novartis Pharmaceuticals Corporation $31.17 10/27/2025 Non-covered Recipient Entity
KANSAS HEART HOSPITAL
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190307889
Principal investigator 1 Amgen Inc. $4,997.79 09/23/2025 Non-covered Recipient Entity
KANSAS NEPHROLOGY RESEARCH INSTITUTE LLC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246643309
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 08/26/2025 Non-covered Recipient Entity
Kansas Heart Hospital
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220740780
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 08/26/2025 Non-covered Recipient Entity
Kansas Heart Hospital
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220740782
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 08/26/2025 Non-covered Recipient Entity
Kansas Heart Hospital
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220740784
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,056.00 07/28/2025 Non-covered Recipient Entity
KANSAS NEPHROLOGY RESEARCH INSTITUTE LLC
Dapagliflozin in Acute Decompensated Heart Failure No dispute reported 06/30/2026 1185546321
Principal investigator 1 Novartis Pharmaceuticals Corporation $19,824.59 01/27/2025 Non-covered Recipient Entity
KANSAS HEART HOSPITAL
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190307891